Boothbay Fund Management’s Unity Biotechnology UBX Stock Holding History

Boothbay Fund Management’s Portfolio UBX Stock Details UBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,000	Closed	-$46K	–	2193
2021 Q2	$46K	Buy	+1,000	New	+$48.2K	﹤0.01%	1766
2020 Q1	–	Sell	-1,375	Closed	-$99K	–	1067
2019 Q4	$99K	Buy	+1,375	New	+$97K	0.01%	763
2019 Q1	–	Sell	-2,570	Closed	-$418K	–	888
2018 Q4	$418K	Buy	+2,570	New	+$341K	0.06%	304

Other funds holding UBX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FFVM

Founders Fund V Management San Francisco, California $2.16M AUM 77.37% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Boothbay Fund Management's UBX Position: Q3 2021 in Review

Boothbay Fund Management sold out of Unity Biotechnology (UBX) in Q3 2021, closing a stake of 1,000 shares — an estimated $46K sold.

Boothbay Fund Management first reported a position in UBX in Q4 2018 and held it in 3 quarters. The position peaked at $418K in Q4 2018. 84 funds tracked by Wall St. Rank hold UBX as of Q3 2021.

Boothbay Fund Management reported no remaining Unity Biotechnology position as of Q3 2021 after selling out during the quarter.
Boothbay Fund Management sold 1,000 Unity Biotechnology shares in Q3 2021, an estimated $46K.
Boothbay Fund Management first reported a position in Unity Biotechnology in Q4 2018 and held it in 3 quarters.
Boothbay Fund Management's Unity Biotechnology position peaked at $418K in Q4 2018.
84 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2021.

Based on Boothbay Fund Management's 13F filing for Q3 2021, filed 15 Nov 2021.